The heavy selling pressure might have exhausted for Cassava Sciences (SAVA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

Full Year Financial Results 2024 - a pivotal year marking the transition from developer to producer at our flagship Nalunaq mine TORONTO, ONTARIO – 28 March 2025 – Amaroq Minerals Ltd. (AIM, TSX-V, ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints ...

Under the terms of the agreements, Sava Re will provide up to $10m (€9.25m) in line size for ASR's core classes.

Simufilam misses key endpoints again, prompting Cassava to phase out Alzheimer's program and shift to new indications ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in ...

The Company has a portfolio of gold and strategic metal assets in Southern Greenland covering the two known gold belts in the region as well as advanced exploration projects at Stendalen and the Sava ...

And if you’re a fresh graduate trying to break into a highly competitive industry like finance, it’s even worse. To illustrate this point, consider a study done by Glassdoor, which revealed that “On ...

We like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable. Based on the last payment, Oracle was paying only paying out a fraction of earnings, but the ...